Monkeypox Has Potential to Cause Heart Problems

Patient in case study developed myocarditis following monkeypox infection

ACC: A 31-year-old male with confirmed monkeypox infection developed acute myocarditis approximately one week following the onset of monkeypox symptoms, according to a case study published today in JACC: Case Reports.

Monkeypox is a disease caused by the monkeypox virus, part of the same family as the virus that causes smallpox, that causes a pimple or blister-like rash on the hands, feet, face, genitals and other parts of the body. Monkeypox was first reported in the EU in May 2022, as well as the United States and other non-endemic countries, and cases are increasing. Myocarditis, an inflammation of the heart muscle, is typically caused by a viral infection. Myocarditis was previously associated with smallpox infection, a more aggressive virus, and the case study authors said that “by extrapolation, the monkeypox virus could have tropism for myocardium tissue or cause immune-mediated injury to the heart.”

“Through this important case study, we are developing a deeper understanding of monkeypox, viral myocarditis and how to accurately diagnose and manage this disease,” said Julia Grapsa, MD, PhD, editor-in-chief of JACC: Case Reports. “The authors of this study have used CMR mapping, a comprehensive imaging tool, to help with the diagnosis of myocarditis. I commend the authors on this valuable clinical case during a critical time as monkeypox continues to spread globally.”

The patient presented to a health clinic five days following the onset of monkeypox symptoms, including malaise, myalgia, fever and multiple swollen lesions on the face, hands and genitalia. Positive monkeypox infection was confirmed with a PCR swab sample of a skin lesion. The patient returned to the emergency department three days later reporting chest tightness radiating through the left arm.

The patient was admitted to an intensive care unit following initial routine examination with the clinical suspicion of acute myocarditis. The initial ECG showed sinus rhythm with nonspecific ventricular repolarization abnormalities and routine laboratory tests revealed elevated levels of C-reactive protein, creatine phosphokinase (CPK), high-sensitivity troponin I and brain natriuretic peptide (BNP), all of which can indicate stress injury to the heart. The results of the cardiac magnetic resonance (CMR) study performed on the patient were consistent with myocardial inflammation and a diagnosis of acute myocarditis.

“This case highlights cardiac involvement as a potential complication associated with monkeypox infection,” said Ana Isabel Pinho, MD, department of cardiology at São João University Hospital Centre in Portugal and lead author of the study. “We believe that reporting this potential causal relationship can raise more awareness of the scientific community and health professionals for acute myocarditis as a possible complication associated with monkeypox; and might be helpful for close monitoring of affected patients for further recognition of other complications in the future.”

The patient was discharged after one week with a full recovery. The authors said further research is needed to identify the relationship between monkeypox and heart injury.

Monkeypox is transmitted through close contact with lesions, bodily fluids or respiratory droplets. In addition to rash, symptoms may include fever, chills, swollen lymph nodes, respiratory symptoms and muscle aches. Most infections are mild, and symptoms can last between two to four weeks. Vaccination is recommended for individuals who have a known or presumed exposure to the virus.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version